BioSpace News Archive

A new study conducted by The Ohio State University and Abbott showed that half of the adults surveyed living with diabetes did not consume the daily recommended intake of protein, which is associated with lower diet quality, increased carbohydrate intake, and greater physical limitations.

GrayMatters Health, a digital therapeutics start-up company, announced that the BIRD Israel-U.S. Binational Industrial Research and Development Foundation awarded a grant to McLean Hospital and the company to develop a novel solution for the therapy of Major Depression Disorder (MDD).

Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA blood test.

In molecular and cellular biology, cell culture acts as a significant tool for biological research.

Like any other cancer, the treatment for blood cancer needs to be personalized to each patient.

A prosthetics implant is a device that substitutes the missing part of the body artificially that may have been lost due to congenital disorder, disease, or trauma.

Cassava Sciences, Inc. (Nasdaq: SAVA) today announced positive biomarker data from an open-label study of simufilam, the Company’s investigational drug for the treatment of Alzheimer’s disease.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the publication of data from its Phase 1b OVATION 1 Study with GEN-1 in combination with neoadjuvant chemotherapy (NACT) in patients with advanced ovarian cancer in Clinical Cancer Research, a journal of the American Association for Cancer Research.

The second part of the panel discussion will feature the clinical study and clinical data of the first 28 patients treated with ANVS401 in the Company’s ongoing Phase 2a trials.

Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada, at www.SEDAR.com.